CDC test to simultaneously detect coronavirus, influenza given FDA emergency use authorization According to the FDA, combination tests offer less patient discomfort and faster, more comprehensive results The Centers for Disease Control and Prevention has received an emergency use authorization (EUA) from the Food and Drug Administration for a new diagnostic test aimed at simultaneously detecting and differentiating between influenza and the coronavirus, according to a press release Thursday. "With the authorization of these tests, the FDA is helping address concerns in anticipation of this upcoming flu season during the COVID-19 pandemic, which might be especially worrying for some Americans," said FDA Commissioner Dr. Stephen M. Hahn. "This is another example of the FDA working with test developers to bring important diagnostics to Americans. With just one swab or sample, combination tests can be used to get answers to Americans faster. This efficiency can go a long way to providing timely information for those sick with an unknown respiratory ailment." According to the FDA, the combination tests use a single sample from a patient to check for multiple respiratory diseases, including the flu and COVID-19. Combination tests offer many advantages, including less discomfort to patients due to fewer samples being taken and faster, more comprehensive results. In addition, combination tests require fewer supplies, such as swabs and personal protective equipment, and reduce pressure on supply chains for reagents, or substances used to cause chemical reactions. (more on the link) .